U6terrâneâm 'Yghonâut
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
2003-Pickard-Lsd-Trial-Transcript-Gordontoddskinner-01.Pdf
Case 5:00-cr-40104-RDR Document 269 Filed 02/11/03 Page 1 of 131 1 " . 'I 1 IN THE UNITED STATES DISTRICt '"COURT,; '\ i FOR THE DISTRICT OF KANSAS 2 TOPEKA, KANSAS I: 21-1 3 ::'~'":r"r"'" '. v ~.' , 4 UNITED STATES OF AMERICA, :.. , . .-.-.... ------ Plaintiff,) ~ 5 ) vs. ) Case No. 6 ) 00-40104-01/02 WILLIAM L. PICKARD and } 7 CLYDE APPERSON! } ------------- Defendants. } 8 TRANSCRIPT OF VOLUME I OF THE TESTIMONY OF 9 GORDON TODD SKINNER HAD DURING TRIAL BEFORE 10 HONORABLE RICHARD D. ROGERS and a jury of 12 11 on January 28, 2003 12 13 APPEARANCES: 14 For the Plaintiff: Mr. Gregory G. Hough Asst. U.S. Attorney 15 290 Federal Building 444 Quincy Street 16 Topeka, Kansas 66683 17 For the Defendant: Mr. William Rork (Pickard) Rork Law Office 18 1321 SW Topeka Blvd. Topeka, Kansas 66612 19 20 For the Defendant: Mr. Mark Bennett (Apperson) Bennett, Hendrix & Moylan 21 5605 SW Barrington Court S Topeka, Kansas 66614 22 Court Reporter: Kelli Stewart! CSR, RPR 23 Nora Lyon & Associates 1515 South Topeka Avenue 24 Topeka, Kansas 66612 25 NORA LYON & ASSOCIATES, INC. 1515 S.W. Topeka Blvd., Topeka, KS 66612 Phone: (785) 232-2545 FAX: (785) 232-2720 ?Jo~ Case 5:00-cr-40104-RDR Document 269 Filed 02/11/03 Page 2 of 131 1 I N D E X ~ 2 Certificate------------------- 131 3 4 WIT N E S 5 ON BEHALF OF THE GOVERNMENT: PAGE 6 GORDON TODD SKINNER 7 Direct Examination by Mr. Hough 3 8 9 10 11 12 13 '-' 14 15 16 17 18 19 20 21 22 23 24 25 NORA LYON & ASSOCIATES, INC. -
Neuropsychedelia
Neuropsychedelia The Revival of Hallucinogen Research since the Decade of the Brain Nicolas Langlitz UNIVERSITY OF CALIFORNIA PRESS Berkeley • Los Angeles • London Contents. University of California Press, one of the most distinguished university presses in the United States, enriches lives around the world by advancing scholarship in the humanities, social sciences, and natural sciences. Its activities are supported by the UC Press Foundation and by philanthropic contributions from individuals and institutions. For more information, visit www.ucpress.edu. University of California Press Berkeley and Los Angeles, California University of California Press, Ltd. London, England © 2013 by The Regents of the University of California Acknowledgments Vtl Library of Congress Cataloging-in-Publication Data Introduction: Neuropsychopharmacology Langlitz, Nicolas, 1975-. Neuropsychedelia : the revival of hallucinogen as Spiritual Technology I research since the decade of the brain I Nicolas Langlitz. 1. Psychedelic Revival p. cm. Includes bibliographical references and index. 2. Swiss Psilocybin and US Dollars 53 ISBN 978-0-520-27481-5 (cloth: alk. paper) ISBN 978-0-520-27482-2 (pbk. : alk. paper) 3. The Varieties of Psychedelic Lab Experience I. Hallucinogenic drugs-Research. 2. Neuropsychopharmacology. 3. Hallucinogenic 4. Enacting Experimental Psychoses 2 drugs and religious experience. 1. Title. I3 BF209·H34L36 2013 - I54·4-dc23 5. Between Animality and Divinity I66 2012022916 6. Mystic Materialism 2°4 Manufactured in the United States of America Conclusion: Fieldwork in Perennial Philosophy 243 21 20 19 18 17 16 15 14 13 10 9 8 7 6 5 4 3 2 In keeping with a commitment to support Notes environmentally responsible and sustainable printing practices, UC Press has printed this book on 50-pound Bibliography Enterprise, a 30% post-consumer-waste, recycled, Index deinked fiber that is processed chlorine-free. -
US Censors LSD Trial, Double Life Sentence Without Parole
FACT exposé : US censors LSD trial, double life sentence without parole The Strange Trip and Fall of Leonard Pickard Criminal Injustice in the Heartland CJ Hinke [email protected] Freedom Against Censorship Thailand (FACT) http://facthai.wordpress.com More than 13 million Americans have tried LSD. US President John F. Kennedy himself engaged in LSD sessions with his lover Mary Pinchot with acid supplied by Timothy Leary. His brother, US Attorney General Robert F. Kennedy, was a vocal critic of the LSD ban; his wife, Ethel, was successfully treated for alcoholism in LSD sessions at Vancouver’s Hollywood Hospital, under the auspices of the International Association for Psychedelic Therapy, which claimed a success rate of 80%. Both brothers were assassinated; few know that Pinchot was also assassinated in her Washington apartment in 1964; her address book was never found. This article addresses another kind of assassination, life sentences for LSD. Nike Atlas Minuteman ICBM The heartland of the United States is riddled with hundreds of nuclear missile silos, now relics of the cold war. Many of these 20+ acre properties were sold to individuals including those doomsday proponents who saw them as the perfect place for survival come Armageddon. The silos have 47-ton fortified blast doors and a 66,000-pound battery bank. They also seem to be popular as a great modern location for server farms and hacker camps. Wamego, Kansas, is the heart of the heartland and welcomed the silos for their government employment opportunities in the country’s farm belt. Waumego was named after Potawatomie chief Waumego but all the Potawatomies were killed in the American Indian Wars in frontier massacres during the mid-1800s. -
Methoxetamine: from Drug of Abuse to Rapid-Acting Antidepressant ⇑ M
Medical Hypotheses 79 (2012) 504–507 Contents lists available at SciVerse ScienceDirect Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy Methoxetamine: From drug of abuse to rapid-acting antidepressant ⇑ M. Coppola a, , R. Mondola b a Department of Addiction, ASL CN2, Viale Coppino 46, 12051 Alba (CN), Italy b Department of Mental Health, ASL CN1, Via Torino 70/B, 12037 Saluzzo (CN), Italy article info abstract Article history: Methoxetamine is a dissociative anaesthetic showing pharmacodynamic similarities with its analogue Received 3 May 2012 ketamine, a medication with demonstrated rapid-acting antidepressant effects. Like ketamine and other Accepted 5 July 2012 arylcyclohexylamine compounds, methoxetamine is thought to be both a noncompetitive NMDA recep- tor antagonist and a dopamine reuptake inhibitor. Furthermore, it acts as an agonist at dopamine D2, serotonin 5HT2, muscarinic cholinergic, sigma-1, opioid mu and k receptors. The hypothesis is that meth- oxetamine can produce rapid antidepressant effects in patients with resistant and non-resistant unipolar and bipolar depression. Ó 2012 Elsevier Ltd. All rights reserved. Introduction N-methyl-D-aspartate (NMDA) receptors produced antidepressant effects in animal models of depression [17,18]. In recent years, Mood disorders (MD) are chronic, recurring, disabilitating psy- some clinical studies have shown that an intravenous dose of ket- chiatric illnesses that affect millions people worldwide [1,2].In amine, an N-methyl-D-aspartate (NMDA) receptor antagonist, pro- particular, major depressive disorder (MDD) is a seriously disabling duces a rapid antidepressant response within hours [19]. These public health problem that produces severe psycho-physical and studies include the treatment of resistant BD in two double-blind, socioeconomic consequences in the population [3]. -
A Full Cycle of Mental Wellness from Research to Remedy
A Full Cycle of Mental Wellness From Research to Remedy CORPORATE PRESENTATION MAY 21, 2021 CSE:MCUR | OTC:MCURF | FRA:6MH Disclaimer & Forward Looking Statements This presentation (the “Presentation”) by MINDCURE Health Inc. (“MINDCURE”) is dated as of May 10, 2021. It is information or delivered. In this Presentation, forward-looking information includes, but is not limited to: statements pertaining to in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or the research, development and commercialization of technology, intellectual property or related products, or the timing potential investors and does not take into account the investment objectives, financial situation or needs of any particular thereof; the likelihood of success of any clinical trials; the likelihood of obtaining regulatory approval; the likelihood of investor. obtaining patents or the efficacy of such patents once granted; the leadership team; the potential for the markets that MINDCURE is anticipating to access; and the factors described under the caption “Risk Factors” in MINDCURE’s final INDUSTRY INFORMATION prospectus dated February 3, 2021 and documents incorporated by reference therein, and other documents publicly This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe filed by MINDCURE, which are available on MINDCURE’s profile at www.sedar.com for securities. This Presentation is not and under no circumstances is to be construed as a prospectus, offering memorandum, advertisement or public offering of any securities referred to herein, nor shall it or any part of it form Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment assumptions of management at the date the statements are made, including among other things, assumptions about: whatsoever. -
The Experiences of Kratom Users in Southern California
THESIS CALIFORNIA ST A TE UNIVERSITY SAN MARCOS THESIS SIGNATURE PAGE THESIS SUB1\.11TTEDIN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE MASTER OF ARTS IN SOCIOLOGICAL PRACTICE TITLE: The Experiences ofKratom Users in Southern California: A Sociological Explanation AUTHOR: Claudia Lacher DATE OF SUCCESSFUL DEFENSE: April 30, 2021 THE THESIS HAS BEEN ACCEPTED BY THE THESIS COM1\.11TTEEIN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF ARTS IN SOCIOLOGICAL PRACTICE Christopher Bickel 05/07/2021 COM1\.11TTEE CHAIR SIGNATURE DATE Richelle Swan 05/07/2021 COM1\.11TTEEMEMBER SIGNATURE DATE Xuan Santos 05/07/2021 XoaIISaIItos(May 7,202113.371=e,f1 COM1\.11TTEEMEMBER SIGNATURE DATE COM1\.11TTEEMEMBER SIGNATURE DATE Table of Contents ACKNOWLEDGEMENTS ........................................................................................................... 2 ABSTRACT .................................................................................................................................. 4 INTRODUCTION ........................................................................................................................ 5 STATEMENT OF THE PROBLEM ............................................................................................. 6 LITERATURE REVIEW .............................................................................................................. 8 PHARMACOLOGY OF MITRAGYNA SPECIOSA ............................................................ 9 FROM EAST TO WEST: A Historical Tale of -
Bath Salts Or Methylenedioxypyrovalerone (MDPV)
New Highs for the New Millennium Brandon J. Warrick MD Assistant Clinical Professor Wayne State University Disclosures • No financial disclosures • All treatments mentioned in this talk are FDA approved. • Treatment dosing may exceed package insert Objectives • What are “Bath Salts”? • What is “Spice or K2”? • Epidemiology • Were did designer drugs come from? • Were are designer drugs going? What are “Bath Salts”? Testimonials • “I don’t believe in the hype so I ordered some offline and received in roughly a week and a half. It came in a 250mg package that ran me roughly 18 dollars with tax and shipping included. I tried roughly 10mg and absolutely loved it. Immediately after ingestion of the bath salts I felt a rush of energy and even a slight euphoria to go along with it. My mind felt like it was working in overdrive and I wanted to talk to anyone about anything I possibly could…” • “At about 1 hour and 10 minutes in I got the strongest urge to redose I have ever felt from a drug, including cocaine.” Physical Properties • White to Light Brown • Hydrophilic • Crumbly powder • Slight odor Michigan; How it Began • First call December 18, 2010 • First Death February 3 2011 • February 2-7 10 cases • Reported – Bay City – Iron Wood – Mt. Clemons PCC & Health Department Need PCC MDCH 24/7 Call Center Yes No Able to give medical advice Yes No Real-time reporting Yes Yes Able to mandate reporting No Yes Able to take legal action No Yes Able to create EPI-X alerts* Yes Yes Able to create HAN* No Yes Able to submit MMWR* No Yes Participates in -
3~/3I·-I!.-- -Against- Index No.: Rjino.: DAN HEINS, Doing Business As SHINING STAR ENTERPRISES
SUPREME COURT OF THE STATE OF NEW YORK COUNTY OF ALBANY PEOPLE OF THE STATE OF NEW YORK, by ERIC T. SCHNEIDERMAN, Attorney General of the State ofNew York, Petitioner, AFFIRMATION 3~/3i·-I!.-- -against- Index No.: RJINo.: DAN HEINS, doing business as SHINING STAR ENTERPRISES, Respondent. DEANJ'JA R. NELSON, an attorney duly admitted to practice law in the State of New York, affirms the following under the penalties of perjury: 1. I am an Assistant Attorney General In Charge in the office of Eric T. Schneiderman, Attorney General of the State of New York (OAG), assigned to the Watertown Regional Office. I am fully familiar with the facts and circumstance of this proceeding, which are based on investigative materials contained in the files of the Attorney General's office. 2. I submit this Affirmation in support of Petitioner's application for an Order and Judgment permanently enjoining Respondent from engaging in deceptive, fraudulent and illegal business practices, requiring that Respondent produce an accounting of mislabeled and misbranded products sold and awarding and penalties and· costs to the State ofNew York 3. Unless otherwise indicated, I make this affirmation upon information and .belief, based upon my investigation, a review of documents and other evidence on file with the Department of Law. Annexed hereto in support of this petition are the fo Howing documents: Ex. I. Affidavit of Senior Investigator Chad Shelmidine, dated 7/6/12, together with Exhibits A-K; Ex. II. Affidavit of Dr. Maja Lundborg-Gray, M.D., FAAEM, FACEP, sworn to on July 5,2012, together with Exhibits A-G; Ex. -
Corporate Presentation, April 2021
Corporate Presentation, April 2021 CSE:MCUR | OTC:MCURF | FRA:6MH Disclaimer This presentation (the “Presentation”) by MINDCURE Health Inc. (“MINDCURE”) is dated as of February, 2021. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. INDUSTRY INFORMATION This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities. This Presentation is not and under no circumstances is to be construed as prospectus, offering memorandum, advertisement or public offering of any securities referred to herein, nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of MINDCURE are referred to the entire body of publicly disclosed information regarding MINDCURE. The information is subject to material updating, revision and further amendment, and is qualified entirely by reference to MINDCURE’s publicly disclosed information. This Presentation includes market and industry data and forecasts that have been obtained from third party sources, including industry publications. MINDCURE believes that the industry data and forecasts are generally reliable and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. -
BREAKING CONVENTION 4Th International Conference On
B REAKING C ONVENTION 4th International Conference on Psychedelic Consciousness 30 JUNE - 2 JULY 2017 UNIVERSITY OF GREENWICH, LONDON CONTENTS Front cover artwork: Cuteness Mania by Maura Holden Introduction 1 Abstracts (Alphabetically by Presenter) 2-33 Programme (Friday) 34-37 Programme (Saturday) 38-42 Programme (Sunday) 43-46 Installations 47 Special Events 48-49 Workshops & Cyberdelics Abstracts 50-52 Wasson Workshops 50 Cyberdelics Workshops 51 Film Festival 52-57 Visionary Art 58 Performances 59 Evening Entertainments 60 Invited Speaker & Committee Bios 61-71 Sponsors 72-79 Acknowledgements 80 University Map 81 Area Map 82 Venue Map 83-84 General Info 85 The Team 86 Safer Spaces Policy 87-89 Notes 90-91 BREAK TIMES - ALL DAYS 11:00 - 11:30 Break 13:00 - 14:30 Lunch 16:30 - 17:00 Break INTRODUCTION PRESENTER ABSTRACTS Adam A. Aronovich Sunday 2nd, 15:00, Eisner’s Entrance Hall Broadening Our Definitions Of Normalcy And Sanity: Crafting Alliances For Cognitive Liberty, Neurodiversity, And Non-Pathologizing Approaches To Mental Health. In common with prohibitive drug policies, western biopsychiatry tends to pathologise many expressions of human di- versity with narrow definitions of normalcy and sanity. An ethnographic approach to mental illness, however, unveils a variety of ways in which mental affliction is experienced, both cross-culturally and intra-culturally. Many non-ordinary experiences and states of awareness are not universally understood to be observable signs of mental disease but can be understood to be meaningful experiences -
In This Issue
EErowidA Psychoactiverow iPlantsd andEExtracts Chemicalsxtra Newslettercts June 2004 Number 6 e at Erowid are generally media referrers for the fi rst week after they were Erowid.org is a member-supported shy and tend to want to focus the published (spots usually occupied by the organization working to provide free, W project’s limited resources on search engines). data and technology rather than on promotion reliable and accurate information Despite our reticence, it is clear that or media attention. But last year we were about psychoactive plants and getting positive media attention helps bring convinced by a couple of friends that if we chemicals. in new support and introduces the site to continued to rebuff even friendly media people who aren’t familiar with it. It’s easy, The information on the site is inquiries, we were passively tipping the buried in Erowid Central, to imagine that a compilation of the experiences, scales towards those journalists who would everyone who’s interested in psychoactive words, and efforts of hundreds of write about the project without actually plants and chemicals already knows about individuals including parents, health talking to us. It seemed likely that these all the major online resources and at least professionals, doctors, therapists, people would be less sympathetic in their has stopped by Erowid in a search. But that chemists, researchers, teachers, writing than those who were kind enough to is clearly not the case. lawyers and those who choose to take “no” for an answer. use psychoactives. Erowid acts as As the project edges over 30,000 unique In early April, Seattle’s weekly alternative a publisher of new information as visitors per day and we consider the impact paper The Stranger published a full-page well as a library for the collection our site may have on those newly exposed editorial about Erowid. -
Forbidden Knowledge Film
NEH Application Cover Sheet (TD-254004) Media Projects Development PROJECT DIRECTOR Mr. Micha Xavier Peled E-mail: [email protected] Director Phone: (415)305-5998 839 Broderick St. Fax: San Francisco, CA 94115-4424 USA Field of expertise: Filmmaking INSTITUTION Teddy Bear Films Inc. San Francisco, CA 94115-4424 APPLICATION INFORMATION Title: FORBIDDEN KNOWLEDGE: Psychedelics & Science Grant period: From 2017-05-01 to 2017-11-01 Project field(s): Interdisciplinary Studies, Other Description of project: Forbidden Knowledge: Psychedelics & Science explores our Western culture’s long, turbulent relationship with psychedelic substances across time. The recently permitted medical trials using hallucinogens form the film’s core, which are otherwise still illegal. Following a number of, PTSD victims through their psychedelic-assisted therapy will provide the film’s dramatic arc and help viewers judge these experiments for themselves. This is the first time camera access is granted to film participants before, during and after such a trial. The film will also shed light on neuroscientists’ explorations of the brain’s inner workings through psychedelics, and on the spiritual dimensions they induce. Critics and skeptics of will give voice to concerns about the safety and value of psychedelic research. Placing the topic in a broad cultural and philosophical context, the film will braid together historical and present-day narratives, employing perspectives from both the sciences and humanities. BUDGET Outright Request 75,000.00 Cost Sharing 6,130.00 Matching Request 0.00 Total Budget 81,130.00 Total NEH 75,000.00 GRANT ADMINISTRATOR Mr. Micha Xavier Peled E-mail: [email protected] 839 Broderick St.